BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freriksen JJM, van Seyen M, Judd A, Gibb DM, Collins IJ, Greupink R, Russel FGM, Drenth JPH, Colbers A, Burger DM. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther. 2019;50:738-750. [PMID: 31448450 DOI: 10.1111/apt.15476] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 El-sayed MH, Indolfi G. Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Semin Liver Dis 2020;40:213-24. [DOI: 10.1055/s-0040-1708812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Eames JR, Tran B. Hepatitis C. Physician Assistant Clinics 2021;6:555-68. [DOI: 10.1016/j.cpha.2021.05.002] [Reference Citation Analysis]
3 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
4 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Squires JE, Balistreri WF. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. The Journal of Pediatrics 2020;221:12-22.e1. [DOI: 10.1016/j.jpeds.2020.02.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jiang X, Song HJ, Wang W, Henry L, Childs-Kean LM, Re VL 3rd, Park H. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. J Manag Care Spec Pharm 2021;27:873-81. [PMID: 34185563 DOI: 10.18553/jmcp.2021.27.7.873] [Reference Citation Analysis]
7 Freriksen JJM, van Seyen M, Judd A, Gibb DM, Collins IJ, Greupink R, Russel FGM, Drenth JPH, Colbers A, Burger DM. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther. 2019;50:738-750. [PMID: 31448450 DOI: 10.1111/apt.15476] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
8 Behnke C, Nissim O, Simerlein W, Beeker K, Tarleton JL, Lazenby GB. Quality improvement to evaluate and provide treatment for chronic hepatitis C postpartum. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00553-7. [PMID: 34975005 DOI: 10.1016/j.japh.2021.12.006] [Reference Citation Analysis]
9 Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
10 Seto MT, Cheung KW, Hung IFN. Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol 2020;68:44-53. [PMID: 32305262 DOI: 10.1016/j.bpobgyn.2020.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wilson RD. Directive clinique no 409 : Tests diagnostiques fœtaux intra-utérins en cas d'infection virale chronique maternelle. J Obstet Gynaecol Can 2020;42:1563-1570.e1. [PMID: 33308792 DOI: 10.1016/j.jogc.2020.10.006] [Reference Citation Analysis]
12 Wilson RD. Guideline No. 409: Intrauterine Fetal Diagnostic Testing in Women with Chronic Viral Infections. J Obstet Gynaecol Can 2020;42:1555-1562.e1. [PMID: 33308791 DOI: 10.1016/j.jogc.2020.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Eleje GU, Rabiu A, Mbachu II, Akaba GO, Loto OM, Usman HA, Fiebai PO, Chukwuanukwu RC, Joe-Ikechebelu NN, Nwankwo CH, Kalu SO, Onubogu CU, Ogbuagu CN, Chukwurah SN, Uzochukwu CE, Inuyomi SO, Adesoji BA, Ogwaluonye UC, Emeka EA, Egeonu RO, Igue OE, Jibuaku CH, Okoro OD, Aja PO, Chidozie CP, Ibrahim HS, Aliyu FE, Numan AI, Omoruyi SA, Oppah IC, Anyang UI, Ahmed A, Umeononihu OS, Umeh EO, Nweje SI, Ajuba IC, Okoro CC, Onwuegbuna AA, Igbodike EP, Nwaeju IK, Yakasai IA, Ezechi OC, Ikechebelu JI. Awareness and prevalence of hepatitis C virus infection among pregnant women in Nigeria: A national pilot cross-sectional study. Womens Health (Lond) 2021;17:17455065211031718. [PMID: 34256625 DOI: 10.1177/17455065211031718] [Reference Citation Analysis]
14 Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, Hosamirudsai H, Afhami S, Akbarpour E, Aliannejad R, Radmard AR, Davarpanah AH, Levi J, Wentzel H, Qavi A, Garratt A, Simmons B, Hill A, Merat S. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020;75:3379-85. [PMID: 32812039 DOI: 10.1093/jac/dkaa334] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 20.0] [Reference Citation Analysis]
15 Neary M, Owen A, Olagunju A. Pharmacokinetics of HIV therapies in pregnant patients: an update. Expert Opin Drug Metab Toxicol 2020;16:449-61. [PMID: 32271621 DOI: 10.1080/17425255.2020.1754792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]